THYROID CANCERS

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.

The approval of selpercatinib marks the first targeted therapy for pediatric patients with RET gene alterations in solid and thyroid tumors.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a patient with NTRK fusion–positive cancer.

A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.

Lova Sun, MD, MCSE, discussed genetic mutations in thyroid cancer and how they impact clinicians’ treatment options.

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Marcia S. Brose, MD, PhD, FASCO, discusses potential next steps for approaching and treating patients with advanced or metastatic RET-mutant thyroid cancer.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Whole-exome sequencing identified genetic mutations associated with poorly differentiated thyroid cancer, paving a new path for research in the field.

Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, discusses treatment sequencing practices and offers advice for community oncologists treating patients with RAI-R-DTC.

Focusing on lenvatinib, an expert on RAI-R-DTC discusses data on real-world treatment patterns and clinical outcomes and gives an overview of papers on age and dose.

Marcia S. Brose, MD, PhD, discusses her experience with lenvatinib as a treatment for patients with RAI-R-DTC.

An expert on radioiodine-refractory differentiated thyroid cancer outlines factors to consider when selecting appropriate treatments for patients.

Clinical insights on the standard-of-care treatment of patients with advanced RAI-R-DTC, the NCCN guideline recommendations, and challenges encountered in treatment.

Marcia S. Brose, MD, PhD, discusses the frontline treatment landscape for patients with advanced RAI-R-DTC, focusing on sorafenib and the DECISION trial as well as lenvatinib and the SELECT trial.

A medical oncologist gives an overview of radioiodine-refractory differentiated thyroid cancer, with a focus on diagnosis and patient presentation.

Marcia S. Brose, MD, PhD, presents the case of a 43-year-old man with radioiodine-refractory differentiated thyroid cancer (RAI-R-DTC) and offers her initial impressions.

Health-related, mental, and emotional quality of life often suffer when patients with thyroid cancer undergo thyroidectomy. However, research shows it may be only in the short-term.

Francis P. Worden, MD, discusses the efficacy findings from the phase 3 COSMIC-311 study of cabozantinib in thyroid cancer.